Oral Motor Intervention to Preterms by Their Mothers
Launched by MARMARA UNIVERSITY · Jan 4, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special feeding technique, called Oral Motor Intervention (PIOMI), can help premature babies who have trouble feeding after leaving the neonatal intensive care unit. The goal is to teach mothers how to use this technique to improve their babies' feeding skills and strengthen the bond between mother and child. The study will evaluate the changes in the babies' ability to feed and how this practice affects their relationship with their mothers.
To participate in the study, babies must have been born before 37 weeks of pregnancy and be in stable health without any swallowing problems or serious medical conditions. Families must agree to take part in the trial. If you have a premature baby who meets these criteria, this study might be a good opportunity to receive support in feeding your little one. The trial is not yet recruiting, so you will need to wait for updates on when you can join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participation in the study is accepted by the family
- • PIOMI can be applied and whose clinical condition is stable,
- • Born earlier than 37 weeks,
- • Those who have not been diagnosed with any disorder in swallowing functions,
- • Without congenital anomalies and systemic diseases,
- • Vital signs are stable,
- • Babies without congenital anomalies or serious complications
- Exclusion Criteria:
- • Participation in the study is not accepted by their family,
- • Those with congenital anomalies and systemic diseases.
- • Those who have been diagnosed with swallowing disorder,
- • Those with congenital disorders or birth trauma,
- • Diagnosed with severe asphyxia,
- • Those with intraventricular bleeding,
- • Those with Neonatal Abstinence Syndrome,
- • Those with Fetal Alcohol Syndrome,
- • Babies connected to a ventilator
About Marmara University
Marmara University is a distinguished academic institution located in Istanbul, Turkey, renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust infrastructure and a multidisciplinary approach, the university actively engages in the development and evaluation of new therapeutic interventions, fostering collaboration among researchers, clinicians, and industry partners. Marmara University’s focus on ethical standards and patient safety underscores its dedication to contributing valuable insights to the medical community and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Maltepe, Turkey
Patients applied
Trial Officials
Aylin Demirci, PT
Principal Investigator
Marmara University
Evrim Karadag Saygi, Prof
Study Director
Marmara University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported